ENXTPA:SANPharmaceuticals
A Look At Sanofi (ENXTPA:SAN) Valuation After Venglustat Priority Review And Expanded AI Push
Why Sanofi’s latest drug and AI updates matter for the stock
The recent priority review for Sanofi (ENXTPA:SAN) venglustat in type 3 Gaucher disease, together with its expanded AI partnership with Owkin, has pushed the stock back into focus for many investors.
See our latest analysis for Sanofi.
Sanofi’s €76.44 share price has picked up in the near term, with a 1 day share price return of 3.97% and a 1 month share price return of 3.07%. This is occurring even though the 1 year total...